Evidence map›Paper›PMID 40033314›Full record

ArticleBMC chemistry2025

Nanao/organocatalyat SiO

Leila Amiri-Zirtol, Zahra Karimi, Javad Farahbakhsh, Ahmad Gholami, Seyedeh Narjes Abootalebi

Abstract read
In one paragraph

Article in BMC chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Leila Amiri-ZirtolBiotechnology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Zahra KarimiSchool of Chemical, Petroleum and Gas Engineering, Iran University of Science and Technology (IUST), Tehran, Iran.
Javad FarahbakhshSchool of Engineering, Edith Cowan University, 270 Joondalup Drive, Joondalup, Perth, WA, 6027, Australia.
Ahmad GholamiBiotechnology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Gholami@sums.ac.ir.
Seyedeh Narjes AbootalebiBiotechnology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Abootalebinarjes@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, a new nanocomposite comprising 4-(2-Aminoethyl)-morpholine, an organic catalyst, was prepared on the surface of silica. The absence of metal in the catalyst structure contributes to its environmental friendliness. This novel nanocatalyst was used for multi-component reactions (MCRs). Having a nano size for the composite enhances the contact between the raw materials and the catalytic surface, leading to significant advancement in the reaction. The synthesized composite was identified and evaluated using FT-IR, EDX, EDX-Mapping, TGA, XRD, BET, TEM, and FE-SEM analysis. The characteristic analysis confirmed the synthesis of both nano-silica/4-(2-Aminoethyl)-morpholine catalyst and polyhydroquinoline. The composite's catalytic properties for synthesizing some polyhydroquinoline derivatives were investigated, yielding promising and remarkable results with high 95% yields and short reaction times. The antibacterial properties of the synthesized compounds were also examined against four types of pathogenic bacteria. The highest inhibitory effect was attributed to the compound Ethyl-4-(3-hydroxyphenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate exhibited the highest antibacterial properties.

Indexed as

4-(2-Aminoethyl)-morpholineAntibacterialCatalystGreen chemistry

Identifiers

PMID40033314
PMCPMC11874776

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.